{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:58:20Z","timestamp":1790441900692,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-026-01032-8","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:13:22Z","timestamp":1789456402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-powered histopathology classifiers identify transcriptomic biomarkers associated with cell cycle regulation and increased mitotic activity in poorly differentiated neuroendocrine carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Timothy","family":"Khumpan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1125-8305","authenticated-orcid":false,"given":"Kasonde","family":"Chewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Vijayvergia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Eleam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Nicolas","family":"Qui\u00f1ones-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Yulan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Engstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy Q.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnaz D.","family":"Alekbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-7326","authenticated-orcid":false,"given":"Kerry S.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan R.","family":"Whetstine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Astsaturov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-3192","authenticated-orcid":false,"given":"Hayan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"1032_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12022-016-9447-2","volume":"27","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Marinoni I, Blank A, Perren A. New genetics and genomic data on pancreatic neuroendocrine tumors: implications for diagnosis, treatment, and targeted therapies. Endocr Pathol. 2016;27:200\u20134.","journal-title":"Endocr Pathol"},{"key":"1032_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa A, Chang DK, Nones K, Corbo V, Patch A-M, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65\u201371.","journal-title":"Nature"},{"key":"1032_CR3","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-19-0214","volume":"79","author":"SV Laddha","year":"2019","unstructured":"Laddha SV, da Silva EM, Robzyk K, Untch BR, Ke H, Rekhtman N, et al. Integrative genomic characterization identifies molecular subtypes of lung carcinoids. Cancer Res. 2019;79:4339\u201347.","journal-title":"Cancer Res"},{"key":"1032_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00428-017-2177-0","volume":"471","author":"C Marchi\u00f2","year":"2017","unstructured":"Marchi\u00f2 C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, et al. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch. 2017;471:713\u201320.","journal-title":"Virchows Arch"},{"key":"1032_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/er.2018-00160","volume":"40","author":"A Mafficini","year":"2019","unstructured":"Mafficini A, Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev. 2019;40:506\u201336.","journal-title":"Endocr Rev"},{"key":"1032_CR6","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","volume":"26","author":"A Puccini","year":"2020","unstructured":"Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, et al. Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Clin Cancer Res. 2020;26:5943\u201351.","journal-title":"Clin Cancer Res"},{"key":"1032_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: Are there global differences? Curr Oncol Rep. 2021;23:43.","journal-title":"Curr Oncol Rep"},{"key":"1032_CR8","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","volume":"23","author":"BE White","year":"2022","unstructured":"White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, et al. Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: a retrospective, population-based study. Lancet Reg Health Eur. 2022;23:100510.","journal-title":"Lancet Reg Health Eur"},{"key":"1032_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/OP.21.00240","volume":"18","author":"JY Zhang","year":"2022","unstructured":"Zhang JY, Kunz PL. Making sense of a complex disease: a practical approach to managing neuroendocrine tumors. JCO Oncology Practice. 2022;18:258\u201364.","journal-title":"JCO Oncology Practice"},{"key":"1032_CR10","doi-asserted-by":"crossref","unstructured":"Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:839\u201368.","DOI":"10.6004\/jnccn.2021.0032"},{"key":"1032_CR11","doi-asserted-by":"crossref","unstructured":"Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015;92\u2013103.","DOI":"10.14694\/EdBook_AM.2015.35.92"},{"key":"1032_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/PAS.0000000000000169","volume":"38","author":"O Basturk","year":"2014","unstructured":"Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38:437\u201347.","journal-title":"Am J Surg Pathol"},{"key":"1032_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1634\/theoncologist.10-2-123","volume":"10","author":"JM Zuetenhorst","year":"2005","unstructured":"Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist. 2005;10:123\u201331.","journal-title":"Oncologist"},{"key":"1032_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"1032_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","volume":"40","author":"LH Tang","year":"2016","unstructured":"Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40:1192\u2013202.","journal-title":"Am J Surg Pathol"},{"key":"1032_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2019","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019;76:182\u20138.","journal-title":"Histopathology"},{"key":"1032_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12022-021-09676-z","volume":"32","author":"S La Rosa","year":"2021","unstructured":"La Rosa S. Challenges in high-grade neuroendocrine neoplasms and mixed neuroendocrine\/non-neuroendocrine neoplasms. Endocr Pathol. 2021;32:245\u201357.","journal-title":"Endocr Pathol"},{"key":"1032_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00795-024-00396-x","volume":"58","author":"K Tsuji","year":"2025","unstructured":"Tsuji K, Abe M, Wakamatsu S, Hoshi S, Hoshi N, Takagi C, et al. Mixed hepatocellular carcinoma and high-grade neuroendocrine neoplasm with ambiguous histopathological features: a case report. Med Mol Morphol. 2025;58:62\u20138.","journal-title":"Med Mol Morphol"},{"key":"1032_CR19","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1172\/JCI67963","volume":"123","author":"MS Banck","year":"2013","unstructured":"Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013;123:2502\u20138.","journal-title":"J Clin Invest"},{"key":"1032_CR20","doi-asserted-by":"crossref","unstructured":"Couvelard A, Cazes A, Cros J. Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know. Best Pract Res Clin Endocrinol Metab. 2023;101795.","DOI":"10.1016\/j.beem.2023.101795"},{"key":"1032_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12022-024-09835-y","volume":"35","author":"NM Joseph","year":"2024","unstructured":"Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, et al. Progression of low-grade neuroendocrine tumors (NET) to high-grade neoplasms harboring the NEC-like co-alteration of RB1 and TP53. Endocr Pathol. 2024;35:325\u201337.","journal-title":"Endocr Pathol"},{"key":"1032_CR22","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","volume":"12","author":"J van Riet","year":"2021","unstructured":"van Riet J, van de Werken HJG, Cuppen E, Eskens FALM, Tesselaar M, van Veenendaal LM, et al. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. Nat Commun. 2021;12:4612.","journal-title":"Nat Commun"},{"key":"1032_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41416-024-02705-8","volume":"131","author":"V Angerilli","year":"2024","unstructured":"Angerilli V, Sabella G, Simbolo M, Lagano V, Centonze G, Gentili M, et al. Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms. Br J Cancer. 2024;131:159\u201370.","journal-title":"Br J Cancer"},{"key":"1032_CR24","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","volume":"28","author":"M Frizziero","year":"2022","unstructured":"Frizziero M, Kilgour E, Simpson KL, Rothwell DG, Moore DA, Frese KK, et al. Expanding therapeutic opportunities for extrapulmonary neuroendocrine carcinoma. Clin Cancer Res. 2022;28:1999\u20132019.","journal-title":"Clin Cancer Res"},{"key":"1032_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13073-022-01018-w","volume":"14","author":"T Simon","year":"2022","unstructured":"Simon T, Riemer P, Jarosch A, Detjen K, Di Domenico A, Bormann F, et al. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. Genome Med. 2022;14:24.","journal-title":"Genome Med"},{"key":"1032_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-20-3281","volume":"27","author":"WM Hackeng","year":"2021","unstructured":"Hackeng WM, Dreijerink KMA, de Leng WWJ, Morsink FHM, Valk GD, Vriens MR, et al. Genome methylation accurately predicts neuroendocrine tumor origin: an online tool. Clin Cancer Res. 2021;27:1341\u201350.","journal-title":"Clin Cancer Res"},{"key":"1032_CR27","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1210\/clinem\/dgaa477","volume":"105","author":"A Tirosh","year":"2020","unstructured":"Tirosh A, Killian JK, Petersen D, Zhu YJ, Walker RL, Blau JE, et al. Distinct DNA methylation signatures in neuroendocrine tumors specific for primary site and inherited predisposition. J Clin Endocrinol Metab. 2020;105:3285\u201394.","journal-title":"J Clin Endocrinol Metab"},{"key":"1032_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-020-01479-y","volume":"3","author":"A Di Domenico","year":"2020","unstructured":"Di Domenico A, Pipinikas CP, Maire RS, Br\u00e4utigam K, Simillion C, Dettmer MS, et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol. 2020;3:1\u201311.","journal-title":"Commun Biol"},{"key":"1032_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano A. nCounter(\u00ae) PanCancer Immune Profiling Panel (NanoString Technologies Inc, Seattle, WA). J Immunother Cancer. 2015;3:42.","journal-title":"J Immunother Cancer"},{"key":"1032_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"1032_CR31","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/cncr.24180","volume":"115","author":"I Drozdov","year":"2009","unstructured":"Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, et al. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer. 2009;115:1638\u201350.","journal-title":"Cancer"},{"key":"1032_CR32","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","volume":"9","author":"CS Chan","year":"2018","unstructured":"Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun. 2018;9:4158.","journal-title":"Nat Commun"},{"key":"1032_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12967-022-03511-7","volume":"20","author":"V Melone","year":"2022","unstructured":"Melone V, Salvati A, Palumbo D, Giurato G, Nassa G, Rizzo F, et al. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J Transl Med. 2022;20:306.","journal-title":"J Transl Med"},{"key":"1032_CR34","doi-asserted-by":"crossref","unstructured":"Sanghvi N, Calvo-Alca\u00f1iz C, Rajagopal PS, Scalera S, Canu V, Sinha S, et al. Charting the transcriptomic landscape of primary and metastatic cancers in relation to their origin and target normal tissues. Sci Adv. 2024;10:eadn0220.","DOI":"10.1126\/sciadv.adn0220"},{"key":"1032_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13148-016-0226-1","volume":"8","author":"K Gall Tro\u0161elj","year":"2016","unstructured":"Gall Tro\u0161elj K, Novak Kujundzic R, Ugarkovic D. Polycomb repressive complex\u2019s evolutionary conserved function: the role of EZH2 status and cellular background. Clin Epigenetics. 2016;8:55.","journal-title":"Clin Epigenetics"},{"key":"1032_CR36","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/2211-5463.12909","volume":"10","author":"H Huang","year":"2020","unstructured":"Huang H, Yang Y, Zhang W, Liu X, Yang G. TTK regulates proliferation and apoptosis of gastric cancer cells through the Akt-mTOR pathway. FEBS Open Bio. 2020;10:1542\u20139.","journal-title":"FEBS Open Bio"},{"key":"1032_CR37","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199\u2013203.","journal-title":"Science"},{"key":"1032_CR38","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s12022-022-09722-4","volume":"33","author":"J Metovic","year":"2022","unstructured":"Metovic J, La Salvia A, Rapa I, Napoli F, Birocco N, Pia Bizzi M, et al. Molecular subtypes of extra-pulmonary neuroendocrine carcinomas identified by the expression of neuroendocrine lineage-specific transcription factors. Endocr Pathol. 2022;33:388\u201399.","journal-title":"Endocr Pathol"},{"key":"1032_CR39","doi-asserted-by":"publisher","first-page":"iii7","DOI":"10.1093\/annonc\/mdy048.001","volume":"29","author":"W Harb","year":"2018","unstructured":"Harb W, Abramson J, Lunning M, Goy A, Maddocks K, Lebedinsky C, et al. A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. Ann Oncol. 2018;29:iii7.","journal-title":"Ann Oncol"},{"key":"1032_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","volume":"129","author":"R Kristeleit","year":"2023","unstructured":"Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, et al. A Phase 1\/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. Br J Cancer. 2023;129:38\u201345.","journal-title":"Br J Cancer"},{"key":"1032_CR41","unstructured":"ClinicalTrials.gov [Internet]. [cited 2026 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05251714"},{"key":"1032_CR42","doi-asserted-by":"publisher","first-page":"1075707","DOI":"10.3389\/fcell.2023.1075707","volume":"11","author":"A Sreekumar","year":"2023","unstructured":"Sreekumar A, Saini S. Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer. Front Cell Dev Biol. 2023;11:1075707.","journal-title":"Front Cell Dev Biol"},{"key":"1032_CR43","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","volume":"12","author":"P Cejas","year":"2021","unstructured":"Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12:5775.","journal-title":"Nat Commun"},{"key":"1032_CR44","doi-asserted-by":"publisher","unstructured":"Colapietra F, Della Monica P, Di Napoli R, Fran\u00e7a Vieira E Silva F, Settembre G, Marino MM, et al. Epigenetic modifications as novel biomarkers for diagnosis, prognosis, and therapeutic targeting in thyroid, pancreas, and lung neuroendocrine tumors. J Clin Med [Internet]. 2025;14. Available from: https:\/\/doi.org\/10.3390\/jcm14082622","DOI":"10.3390\/jcm14082622"},{"key":"1032_CR45","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H, Selth LA. The transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov. 2023;13:1771\u201388.","journal-title":"Cancer Discov"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-026-01032-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-026-01032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-026-01032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:02:05Z","timestamp":1790438525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40246-026-01032-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1186\/s40246-026-01032-8","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants were conducted in accordance with the Declaration of Helsinki. The Institutional Review Boards (IRB) of Fox Chase Cancer Center approved the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.R.W. at Fox Chase Cancer Center has served or is serving as a consultant or advisor for Qsonica, Daiichi Sankyo, Inc., and Vyne Therapeutics in past year. J.R.W. received an honorarium from Arima Genomics and is a co-investigator on a sponsored project. J.R.W also received funding from Oryzon Genomics. K.S.C. received funding from Janssen Pharmaceuticals.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"142"}}